Celyad Oncology SA
XBRU:CYAD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.2295
1
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Celyad Oncology SA
Celyad Oncology SA
Accounts Receivables
Celyad Oncology SA
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celyad Oncology SA
XBRU:CYAD
|
Accounts Receivables
€380k
|
CAGR 3-Years
24%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
M
|
MDxHealth SA
NASDAQ:MDXH
|
Accounts Receivables
$13.5m
|
CAGR 3-Years
46%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
12%
|
|
|
Galapagos NV
AEX:GLPG
|
Accounts Receivables
€60m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Oxurion NV
XBRU:OXUR
|
Accounts Receivables
€316k
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
Celyad Oncology SA
Glance View
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
See Also
What is Celyad Oncology SA's Accounts Receivables?
Accounts Receivables
380k
EUR
Based on the financial report for Jun 30, 2024, Celyad Oncology SA's Accounts Receivables amounts to 380k EUR.
What is Celyad Oncology SA's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
10%
Over the last year, the Accounts Receivables growth was -41%. The average annual Accounts Receivables growth rates for Celyad Oncology SA have been 24% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
